Company intelligence / Profile preview

Immune Design

Seattle, Washington, United Statespmc.ncbi.nlm.nih.gov ↗
Ownership
Private
Employees
~50
Development stage
Phase 2
01

Overview

Immune Design developed two synergistic immunotherapy platforms with clinical programs ranging from preclinical to randomized Phase 2. Their lead candidate G100 showed clinical benefit as an intratumoral TLR4 agonist in multiple tumor types. The company also had ongoing pharmaceutical collaborations for infectious disease and allergy indications

Therapeutic areas
OncologyImmunologyInfectious Diseases
Modalities
Vaccinesbiologicsimmunotherapies (notably *in vivo* dendritic cell-targeting vectors and TLR4 agonists)
Industry
Biotech
02

Drug pipeline

3 assets

CMB305

Phase 2
Indications
Soft tissue sarcoma

2 more assets in the full pipeline.

Request access →
03

Partnerships

Collaborations with pharmaceutical companies for development of infectious disease and allergy indications; three oncology clinical collaborations combining their agents with partners’ therapies as of late-stage operations before the Merck acquisition

Beyond the preview

Go deeper on Immune Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Design.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call